Physician profile
Febin John
NPI 1619385606
$4,156.84
in general payments reported to CMS, 2019-2025
28 companies · $751 in 2025
The $751 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.20 · 2020: $409 · 2021: $961 · 2022: $650 · 2023: $469 · 2024: $897 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,034 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.53 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,713.85 | 2020-2025 | |
| Janssen Biotech, INC. | $693.88 | 2021-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $443.76 | 2020-2024 | Xifaxan, Trulance, Uceris |
| Pfizer INC. | $414.91 | 2023-2025 | |
| Boston Scientific Corporation | $136.78 | 2023 | Spyglass |
| Madrigal Pharmaceuticals | $99.36 | 2025 | Rezdiffra |
| Qol Medical, LLC | $87.43 | 2020-2024 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $61.61 | 2021-2024 | Entyvio |
| Genzyme Corporation | $52.88 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $47.62 | 2021-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $45.48 | 2024-2025 | Iqirvo, Bylvay |
| Redhill Biopharma INC. | $35.61 | 2020-2021 | |
| Ambu INC. | $27.61 | 2021 | |
| Braintree Laboratories, INC. | $26.93 | 2021 | |
| Lilly USA, LLC | $25.61 | 2025 | Omvoh |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $24.18 | 2023 | |
| Celltrion USA INC. | $22.75 | 2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $22.10 | 2024 | Dupixent |
| Amgen INC. | $21.57 | 2023 | Avsola, Amjevita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.20 | 2019 | |
| Aimmune Therapeutics, INC. | $18.96 | 2024 | |
| Phathom Pharmaceuticals, INC. | $18.88 | 2025 | Voquezna |
| Daiichi Sankyo INC. | $17.94 | 2020 | |
| Olympus America INC. | $17.58 | 2021 | |
| Ucb, INC. | $17.49 | 2020 | |
| Gilead Sciences, INC. | $17.20 | 2025 | |
| Celgene Corporation | $15.54 | 2024 | Zeposia |
| Micro-Tech Endoscopy USA, INC. | $10.13 | 2024 | Lesionhunter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Febin John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.